On May 14, 2026, Camp4 Therapeutics Corp announced new preclinical data showing that CMP-002 improves seizure threshold and severity in a model of SYNGAP1-Related Disorder.
AI Assistant
CAMP4 THERAPEUTICS CORP
2026
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.